The U.K. decision to shut down Chiron's Fluvirin vaccine production for a period of time is expected to have repercussions beyond the U.S. since worldwide supplies already were expected to be tight this season. The U.K., which took the action against Chiron based on 4 million doses failing to meet sterility standards, already had faced its own vaccine shortage.

Related Summaries